Summit Investment Advisors Inc. Has $330,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

Summit Investment Advisors Inc. trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 4.2% during the fourth quarter, Holdings Channel reports. The firm owned 1,680 shares of the medical research company’s stock after selling 74 shares during the quarter. Summit Investment Advisors Inc.’s holdings in IQVIA were worth $330,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Synergy Asset Management LLC bought a new position in shares of IQVIA during the 4th quarter worth approximately $33,000. Lee Danner & Bass Inc. acquired a new stake in IQVIA in the fourth quarter worth $44,000. Zions Bancorporation N.A. increased its stake in IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 85 shares in the last quarter. Versant Capital Management Inc raised its holdings in shares of IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. bought a new position in shares of IQVIA during the 4th quarter worth about $60,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 3.2 %

Shares of IQV stock opened at $143.66 on Monday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market cap of $25.33 billion, a P/E ratio of 19.15, a PEG ratio of 1.99 and a beta of 1.46. The company has a 50 day moving average of $176.42 and a 200-day moving average of $196.40. IQVIA Holdings Inc. has a 12-month low of $135.97 and a 12-month high of $252.88.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on IQV. Barclays reaffirmed an “equal weight” rating and set a $170.00 price target (down from $235.00) on shares of IQVIA in a research note on Thursday, April 10th. Stifel Nicolaus reduced their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Morgan Stanley raised their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Citigroup decreased their target price on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Finally, StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Six equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $241.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.